



GARDEN
GLOBAL HEMATOLOGICAL
RARE DISEASES ALLIANCE



FAD SINCRONA ECM / SYNCHRONOUS CME WEBINAR

29 | **November**
2025


Ore 09.00-13.45 (Italian Time)

The **Role** of **Collaboration** between
Regulatory Agencies and Researchers
in promoting innovation for
Hematological Rare Diseases

Scientific Coordinator: Aurelio Maggio

GARDEN
WEBINARS
SERIES

a comprehensive approach
for breaking-up
the common barriers of
hematological
rare
diseases





GARDEN
GLOBAL HEMATOLOGICAL
RARE DISEASES ALLIANCE



GARDEN WEBINARS SERIES

Rare hematological diseases, while individually uncommon, collectively impact millions of lives worldwide. These conditions present significant challenges in terms of early diagnosis, treatment accessibility, and appropriate and effective patient communication. Overcoming these barriers requires a multidisciplinary international network aimed at establishing a common framework for corrective actions.

The role of regulatory agencies in promoting innovation for hematological rare diseases is critical to improving patient outcomes through expedited development and access to novel therapies.

Scientific Coordinator:
Aurelio Maggio

Scientific Committee:
Aurelio Maggio
Stefano Rivella

a comprehensive approach
for breaking-up
the common barriers of
**hematological
rare
diseases**

Their responsibilities include:

Facilitating Accelerated Approval Pathways: Agencies such as the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and others often implement programs like Breakthrough Therapy Designation, PRIME scheme, Priority Review, and Adaptive Pathways to fast-track promising treatments.

Providing Guidance and Support: They issue scientific advice, guidance documents, and frameworks to help researchers and pharmaceutical companies develop therapies tailored to the unique challenges of hematological rare diseases, such as limited patient populations and biomarker validation.

Encouraging Orphan Drug Designation: Regulatory agencies offer incentives like market exclusivity, tax credits, and grants for developing treatments targeted at rare diseases, thus fostering innovation by reducing financial risks.

Supporting Innovative Trial Designs: Promoting adaptive clinical trials, surrogate endpoints, and real-world evidence collection helps accelerate the evaluation process and adapt to the specific needs of rare hematological conditions

Promoting Global Collaboration: Agencies often engage in international cooperation to harmonize standards, share data, and streamline approval processes across borders, thereby increasing access to innovative therapies worldwide.

The **Role** of **Collaboration** between Regulatory Agencies and Researchers in promoting innovation for **Hematological Rare Diseases**

Particularly, EMA and National Regulatory Agencies across EU have established a robust ecosystem of support tools for developers, combining early engagement, regulatory guidance, collaborative networks, compliance resources, and training. These tools are designed to streamline the development and regulatory approval of innovative medicines and health technologies, with a strong emphasis on digital transformation and AI integration. Moreover, a positive benefit-risk balance is essential for marketing authorization. Therefore, Regulatory Agencies work to look at the process as dynamic, according to the evidence-driven, and ensuring that only medicines with a favorable balance of benefits over risks will be available to patients, with ongoing monitoring to safeguard public health. Finally, while drug development for rare diseases faces significant scientific, economic, and regulatory obstacles, Regulatory Agencies make opportunities possible through innovative use of data, technology, policy incentives, and collaborative models. Harnessing these strategies is essential to bring life-changing therapies to patients with rare conditions.

The rapid evolution of treatment options for rare hematological diseases necessitates ongoing education for healthcare professionals on the innovative treatments, on regulatory requirements and available support tools for developers, as well as about the approaches in determining cost vs benefit advantage and the regulation of new tool as AI. This event focuses on several key areas where recent progress has been made in term of academic approaches for the cure of thalassemia, hemophilia and disorders of iron pathways. A model for calculating the cost of gene therapies, according to the different epidemiology of the rare hematological disease in the single country will be presented. Finally, the EMA and EU Regulatory Network approaches to address the challenges posed by innovative technologies and methodologies applied to drug developments will be presented. These issues will be discussed with AIFA representatives who will share their perspective and available support tools for researchers to translate from academic research to the bed of the patient's product. At the end of the webinar, it will be held with the participation of the associations of the patients, the regulatory agencies, the participating KOL, psychologists and the HTA experts.

GARDEN D'AGOSTINO AWARD FOR INNOVATIVE RESEARCH IN HEMATOLOGICAL RARE DISEASES

The D'Agostino Prize for Innovative Research in Hematological Rare Diseases honors outstanding scientific contributions that advance the understanding, diagnosis, or treatment of rare blood disorders

This prestigious award recognizes groundbreaking research that demonstrates creativity, scientific rigor, and the potential to significantly impact patient outcomes in the field of hematology.

All details on the award are shown on <https://garden.fondazionecutino.it>.

The deadline for the presentation of the application is by October 6, 2025 at 2:00 pm.



29 | **November
2025**

Ore 09.00-13.45 (Italian Time)

09.00-09.10

Introduction - A. Maggio

09.10-10.45

FIRST SESSION

Chair: **S. Rivella**

**Challenges and opportunities
of new treatments
in Thalassemia,
Hemophilia and Anemia:
*setting the scene***

09.10-09.30

**Reframing Thalassemia Syndrome
as a benign haematopoietic
stem-cell disorder**

A. Maggio

09.30-09.50

**Translating fundamental biology
of erythropoiesis into the cure
of Thalassemia**

S. Rivella

09.50-10.10

**Molecular approaches for controlling
iron pathways to treat Anemia**

O. Marques

10.10-10.30

**Gene Editing approach for the cure
of Hemophilia**

M. Pinotti

10.30-10.45

Q&A session

All Faculty

The **Role** of **Collaboration** between **Regulatory Agencies** and **Researchers** in promoting innovation for **Hematological Rare Diseases**

10.45-12.45

SECOND SESSION

Chairs: **P. Foggi** (to be confirmed),
A. Maggio

**Challenges and opportunities
of new treatments
in Thalassemia,
Hemophilia and Anemia:
understanding regulatory
requirements and how to make
the best use of new technologies**

10.45-11.10

Challenges and opportunities in
drug development for rare diseases:
regulators perspective

A. Isgrò (to be confirmed)

11.10-11.35

The role of regulators to support innovation
and access to new treatments
for rare diseases

P. Foggi (to be confirmed)

11.35-12.00

The regulatory approaches of EMA
for implementing the appropriate use
of AI in medicine

A. Magrelli (to be confirmed)

12.00-12.25


Opportunities and Challenges
of Artificial Intelligence in Hematology

S. D'Amico

12.25-12.45

Q&A session

All Faculty



**29 | November
2025**

Ore 09.00-13.45 (Italian Time)

12.45-13.30

THIRD SESSION

Chair: **A. Messori**

**How to translate these
new approaches in possible drug
for Thalassemia, Hemophilia,
and Anemia**

12.45-13.05

Inverse relation between the price
of innovative treatments
and disease incidence

A. Messori

13.05-13.25

Impact of joint scientific consultation
and joint clinical evaluation on the future
development and access to new drugs
for rare diseases

P. Rivetti di Val Cervo (to be confirmed)

13.25-13.30

Q&A session

All Faculty

13.30-13.45

Garden D'Agostino Award Ceremony

13.45

Closing remarks - **A. Maggio**

The **Role** of **Collaboration** between **Regulatory Agencies** and **Researchers** in promoting innovation for **Hematological Rare Diseases**

Faculty

D'amico Saverio (Milano, ITA)

Foggi Paolo (Roma, ITA)

Isgro Antonella (Roma, ITA)

Maggio Aurelio (Palermo, ITA)

Magrelli Armando (Roma, ITA)

Messori Andrea (Firenze,, ITA)

Paixao Marques Oriana (Heidelberg, Germany)

Pinotti Mirko (Ferrara, ITA)

Rivella Stefano (Philadelphia, USA)

Rivetti Di Val Cervo Pia (Roma, ITA)

**GARDEN
WEBINARS
SERIES**

a comprehensive approach
for **breaking-up**
the common barriers of
**hematological
rare
diseases**

ECM - EDUCAZIONE CONTINUA IN MEDICINA

Tipologia del Corso: **FAD Sincrona**

Durata formativa: **5 ore**

Crediti ECM: n. **7,5**

ID ECM n°: **275-460423**

Professioni:

- **Medico Chirurgo** (Ematologia, Oncologia)
- **Biologo**
- **Tecnico sanitario laboratorio biomedico**
- **Infermiere**

N. partecipanti previsti: **500**

Obiettivo Formativo: **3 - Documentazione clinica.**

Percorsi clinico-assistenziali diagnostici
e riabilitativi, profili di assistenza - profili di cura

Istruzioni per iscrizioni

Please note that registration for the allocation of ECM credits
is valid exclusively for Italian residents.

- 1) Inquadrare il Qr Code o collegarsi al seguente link:
<https://infomed-ecm.it/event/???/showCard>
- 2) Cliccare su **ISCRIVITI**
- 3) Cliccare su **LOGIN**
(se già registrato alla piattaforma Infomed)
ed effettuare il login con le proprie credenziali.
- 4) Cliccare su **REGISTRATI**
(se non iscritto alla piattaforma Infomed)
per compilare la scheda anagrafica
e procedere all'iscrizione all'evento.



Compilazione Questionario ECM

Al termine dell'incontro, i partecipanti dovranno sostenere un

Test di Valutazione a risposta multipla e compilare il

Modulo di Qualità Percepita tramite la piattaforma:

- numero massimo di tentativi a disposizione: 1
- soglia di superamento: 75% delle risposte corrette

Test di Valutazione e Modulo di Qualità Percepita dovranno
essere compilati entro le ore **24.00** del **01/12/2025**

PROVIDER ECM N. 275 e SEGRETERIA ORGANIZZATIVA



Via San Gregorio, 12 - 20124 MILANO (Italy)

Tel. +39 02 49453331

giovanni.bondanini@infomed-online.it

www.infomed-online.it

Con la sponsorizzazione non condizionante di:
With the unconditional sponsorship of